Longevity Biotech, Inc. is a pioneering biotechnology company focused on developing breakthrough therapeutics using its proprietary Hybridtides® technology. These therapeutics are designed to treat complex diseases such as neuroinflammation and diabetes by leveraging a unique composition of natural and non-natural amino acids. The company's core technology enables the fine-tuning of intracellular signal cascades, optimizing drug efficacy and durability in various biological environments.

Operating in the biotechnology sector, Longevity Biotech serves pharmaceutical companies and healthcare providers looking for advanced treatment options. The company is currently in the preclinical development stage with multiple programs in its pipeline. Its business model involves the development and licensing of its peptide-based drug candidates, generating revenue through partnerships, collaborations, and milestone payments.

Longevity Biotech's innovative approach to oral peptide delivery sets it apart in the market. The company utilizes proprietary databases to optimize absorption parameters, ensuring that its therapeutics achieve the necessary stability, solubility, and absorption for commercial success. By focusing on these critical dimensions, Longevity Biotech aims to bring effective and durable treatments to market, addressing unmet medical needs.

Keywords: peptide therapeutics, neuroinflammation, diabetes, Hybridtides, biotechnology, preclinical development, oral delivery, drug candidates, signal cascades, pharmaceutical partnerships.